This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Nonsteroidal Anti-inflammatory Drug Story

Linda J. Miwa, PharmD, MPH; Judith K. Jones, MD, PhD; Atul Pathiyal; Hind Hatoum, PhD

Arch Intern Med. 1997;157(18):2129-2136.

Abstract
Background
Evidence supporting differential toxic effects of nonsteroidal anti-inflammatory drugs (NSAIDs) often is derived from spontaneous reports of adverse events to the US Food and Drug Administration (FDA). These reports represent observations from an undefined, exposed population that are not collected in a standardized manner and therefore are subject to reporting biases. Epidemiologic studies, in which the numbers of patients experiencing an adverse event and exposed to the drug are known, provide more reliable measures of risk and can place spontaneous reports in perspective.

Objective
To compare both data sources with regard to NSAID-associated gastrointestinal, liver, and skin events.

Methods
We obtained spontaneous reports of these adverse events for diclofenac, nabumetone, naproxen, and piroxicam. Published epidemiologic studies of these events were reviewed.

Results
Spontaneous reports did not mirror reliably the results of epidemiologic studies. Spontaneous reports showed higher associations of gastrointestinal and skin events with nabumetone and piroxicam and hepatic events with diclofenac. Epidemiologic studies generally did not show differential risk among these NSAIDs.

Conclusions
When the 4 NSAIDs are compared in epidemiologic studies, there is no quantitative basis for identifying 1 as more or less toxic than the others, underlining the hazard of deriving quantitative conclusions from spontaneous reports. Spontaneous reports are an unreliable measure of risk; rather, they may provide evidence of the relative awareness of specific toxic effects among physicians.

Arch Intern Med. 1997;157:2129-2136

Author Affiliations
From The Degge Group, Ltd, Arlington, Va (Drs Miwa and Jones and Mr Pathiyal), and G. D. Searle and Company, Chicago, Ill (Dr Hatoum). Drs Miwa and Jones and Mr Pathiyal are employees of The Degge Group, Ltd, which has provided paid consulting services to G. D. Searle and Company. Dr Hatoum was an employee of G. D. Searle and Company at the time of this study.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis
Bae et al.
Rheumatology (Oxford) 2003;42:46-53.
ABSTRACT | FULL TEXT  

Rates of Cutaneous Reactions to Drugs
Bigby
Arch Dermatol 2001;137:765-770.
ABSTRACT | FULL TEXT  

Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection
Sulkowski et al.
JAMA 2000;283:74-80.
ABSTRACT | FULL TEXT  

Time to Act on Drug Safety
Moore et al.
JAMA 1998;279:1571-1573.
FULL TEXT